Reviewed October 23, 2026 · For B2B procurement and development teams
An injection pen program cannot use one generic “FDA and CE” checklist. In the United States, the first task is to determine whether the presentation meets the combination-product definition in 21 CFR 3.2(e), identify the lead center and apply the combination-product current good manufacturing practice framework. In the European Union, an integral medicinal product and device may trigger the medicinal-product dossier requirements amended by Medical Device Regulation Article 117, including device conformity evidence or a notified-body opinion where applicable. The legal manufacturer, medicinal-product applicant, device developer, filler, assembler and brand owner can therefore hold different responsibilities across the two systems. The project should document product configuration, intended use, primary mode of action, market pathway, evidence owner and submission owner before design freeze. HYTANBIO can support the device-development package, but it cannot assign regulatory classification or replace the sponsor’s qualified regulatory and legal assessment.
Scope boundary: This page is a B2B engineering and evidence-planning guide. It is not medical advice, regulatory approval, a drug offer or a compatibility statement for an unnamed configuration.
Decision inputs to control
- Single-entity, co-packaged or cross-labeled presentation
- Primary mode of action and intended use
- U.S. lead-center and application assumptions
- EU integral-product and Article 117 assessment
- Legal manufacturer and submission owner
- Design, drug-product and container evidence ownership
- Quality agreement and record-retention responsibilities
- Market-specific change-notification triggers
Map the exact presentation before comparing jurisdictions
Regulatory planning starts with the physical and labeling relationship between the drug or biological product and the injection device. A prefilled pen, a co-packaged cartridge and reusable pen, and separately supplied products intended for exclusive cross-labeled use can have different consequences. FDA describes several combination-product types under 21 CFR 3.2(e), including single-entity, co-packaged and certain cross-labeled products. The European analysis should separately determine whether the device forms an integral product with the medicine, whether it is reusable or otherwise supplied, and which Medical Device Regulation provisions apply. Record the intended users, use environment, route, dose-setting logic, container, needle strategy and commercial packaging. Do not infer the pathway from a similar marketed product because differences in configuration, claims or supply arrangement can change the analysis. A written jurisdiction memo should state the assumptions, open questions, responsible experts and trigger for reassessment.
Assign evidence and quality-system ownership in the United States
For a U.S. program, the sponsor should document the Office of Combination Products classification basis, the expected lead center and the application type with qualified regulatory counsel. The quality plan should show how applicable drug, biologic and device requirements are satisfied under 21 CFR Part 4 rather than assuming that a supplier certificate covers the finished combination product. Responsibilities commonly include formulation and container-closure evidence, device design controls, risk management, human factors, delivery performance, supplier controls, assembly and filling, labeling, complaint handling, adverse-event reporting and postmarket changes. FDA’s final pen-injector guidance is a useful performance reference, but it does not transfer application ownership to the device supplier. Contracts and quality agreements should identify which party generates, reviews, approves and retains each record. The product sponsor should also control any statement that a particular medicine, container or needle is compatible with the final device.
Build the EU Article 117 evidence route without false equivalence
For an EU integral drug-device product, Article 117 amended the medicinal-product dossier requirements so the device element must be supported by the appropriate conformity evidence. Where the device would require notified-body involvement if marketed separately and a declaration of conformity or CE certificate is not available, a notified-body opinion on relevant general safety and performance requirements may be needed. That route is not the same as a U.S. combination-product submission, and a U.S. clearance or quality-system inspection does not automatically satisfy it. The team should define the medicinal-product applicant, device manufacturer, notified-body interaction owner, technical-documentation boundary, essential-performance evidence, usability, risk management, labeling and change-notification process. Supplier drawings and test reports must be configuration controlled and accessible to the dossier owner. A market-specific gap assessment should be refreshed when the device variant, primary container, manufacturing site, intended use or applicable guidance changes.
Related engineering guides
OEM/ODM Engineering · Packaging and UDI Guide · Request a Project Review
Primary sources and status notes
Use the current official source and its revision status when converting this guide into project requirements. Standards summaries do not replace the purchased standard, and a source identified as draft is not binding or for implementation.
- FDA — Combination Product Definition and Types
- FDA — Current Good Manufacturing Practice Requirements for Combination Products
- EUR-Lex — Regulation (EU) 2017/745, including Article 117
Questions buyers also ask
No. Classification depends on the actual components, packaging, labeling and intended relationship described in 21 CFR 3.2(e).
No. The U.S. and EU frameworks use different legal routes and evidence responsibilities.
Only if the applicable legal roles actually assign that responsibility; most drug-device programs require a documented division among several parties.
Update it after changes to presentation, claims, container, device variant, manufacturing site, market pathway or responsible legal entity.